Overview

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

Status:
Completed

Trial end date:
2018-05-29

Target enrollment:

Participant gender:

Summary

This phase 2 trial evaluatesteh benefit of epacadostat plus pembrolizumab in combination to treat patients with gastroesophageal junction or gastric cancer that has spread to other parts of the body and cannot be removed by surgery. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving epacadostat and pembrolizumab may work better in treating patients with gastroesophageal junction or gastric cancer.

Phase:

Phase 2

Details

Lead Sponsor:

George Albert Fisher
Pamela L. Kunz

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab